Cargando…

NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care

The term non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common type of chronic liver disease. NAFLD points to excessive hepatic fat storage and no evidence of secondary hepatic fat accumulation in patients with “no or little alcohol consumption”. Both the etiology and pathogen...

Descripción completa

Detalles Bibliográficos
Autor principal: Portincasa, Piero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326150/
https://www.ncbi.nlm.nih.gov/pubmed/36807050
http://dx.doi.org/10.1007/s11739-023-03203-0
_version_ 1785069368169725952
author Portincasa, Piero
author_facet Portincasa, Piero
author_sort Portincasa, Piero
collection PubMed
description The term non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common type of chronic liver disease. NAFLD points to excessive hepatic fat storage and no evidence of secondary hepatic fat accumulation in patients with “no or little alcohol consumption”. Both the etiology and pathogenesis of NAFLD are largely unknown, and a definitive therapy is lacking. Since NAFLD is very often and closely associated with metabolic dysfunctions, a consensus process is ongoing to shift the acronym NAFLD to MAFLD, i.e., metabolic-associated fatty liver disease. The change in terminology is likely to improve the classification of affected individuals, the disease awareness, the comprehension of the terminology and pathophysiological aspects involved, and the choice of more personalized therapeutic approaches while avoiding the intrinsic stigmatization due to the term “non-alcoholic”. Even more recently, other sub-classifications have been proposed to concentrate the heterogeneous causes of fatty liver disease under one umbrella. While awaiting additional validation studies in this field, we discuss the main reasons underlying this important shift of paradigm. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-023-03203-0.
format Online
Article
Text
id pubmed-10326150
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-103261502023-07-08 NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care Portincasa, Piero Intern Emerg Med Im - Review The term non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common type of chronic liver disease. NAFLD points to excessive hepatic fat storage and no evidence of secondary hepatic fat accumulation in patients with “no or little alcohol consumption”. Both the etiology and pathogenesis of NAFLD are largely unknown, and a definitive therapy is lacking. Since NAFLD is very often and closely associated with metabolic dysfunctions, a consensus process is ongoing to shift the acronym NAFLD to MAFLD, i.e., metabolic-associated fatty liver disease. The change in terminology is likely to improve the classification of affected individuals, the disease awareness, the comprehension of the terminology and pathophysiological aspects involved, and the choice of more personalized therapeutic approaches while avoiding the intrinsic stigmatization due to the term “non-alcoholic”. Even more recently, other sub-classifications have been proposed to concentrate the heterogeneous causes of fatty liver disease under one umbrella. While awaiting additional validation studies in this field, we discuss the main reasons underlying this important shift of paradigm. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-023-03203-0. Springer International Publishing 2023-02-17 2023 /pmc/articles/PMC10326150/ /pubmed/36807050 http://dx.doi.org/10.1007/s11739-023-03203-0 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Im - Review
Portincasa, Piero
NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
title NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
title_full NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
title_fullStr NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
title_full_unstemmed NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
title_short NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
title_sort nafld, mafld, and beyond: one or several acronyms for better comprehension and patient care
topic Im - Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326150/
https://www.ncbi.nlm.nih.gov/pubmed/36807050
http://dx.doi.org/10.1007/s11739-023-03203-0
work_keys_str_mv AT portincasapiero nafldmafldandbeyondoneorseveralacronymsforbettercomprehensionandpatientcare